KR102506958B1 - Composition Comprising Mesembryanthemum crystalinum Extracts, Pueraria lobata flower Extracts, and Artemisia indica Extracts for Preventing of Alleviating Hangover and Improving Hepatic Function - Google Patents

Composition Comprising Mesembryanthemum crystalinum Extracts, Pueraria lobata flower Extracts, and Artemisia indica Extracts for Preventing of Alleviating Hangover and Improving Hepatic Function Download PDF

Info

Publication number
KR102506958B1
KR102506958B1 KR1020220118110A KR20220118110A KR102506958B1 KR 102506958 B1 KR102506958 B1 KR 102506958B1 KR 1020220118110 A KR1020220118110 A KR 1020220118110A KR 20220118110 A KR20220118110 A KR 20220118110A KR 102506958 B1 KR102506958 B1 KR 102506958B1
Authority
KR
South Korea
Prior art keywords
extract
extracts
alcohol
hem
group
Prior art date
Application number
KR1020220118110A
Other languages
Korean (ko)
Inventor
정승희
김현지
김수아
강희림
우선욱
박수동
심재중
이정열
Original Assignee
주식회사 에치와이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 에치와이 filed Critical 주식회사 에치와이
Priority to KR1020220118110A priority Critical patent/KR102506958B1/en
Application granted granted Critical
Publication of KR102506958B1 publication Critical patent/KR102506958B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38Other non-alcoholic beverages
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/334Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/20Natural extracts
    • A23V2250/21Plant extracts
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00Processes
    • A23V2300/14Extraction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to a food composition comprising a Mesembryanthemum crystalinum extract, a Pueraria lobata flower extract, and an Artemisia indica extract, wherein when ingesting the food composition of the present invention, the present invention has an effect of promoting alcohol metabolism and removing a hangover and protecting a liver function due to protecting the liver cells from alcohol.

Description

아이스플랜트 추출물, 갈화 추출물, 및 쑥 추출물을 포함하는 숙취해소 및 간 기능 개선용 식품조성물 {Composition Comprising Mesembryanthemum crystalinum Extracts, Pueraria lobata flower Extracts, and Artemisia indica Extracts for Preventing of Alleviating Hangover and Improving Hepatic Function}Food composition for relieving hangover and improving liver function containing ice plant extract, brown flower extract, and mugwort extract

본 발명은 아이스플랜트 추출물, 갈화 추출물, 및 쑥 추출물을 포함하는 숙취해소 및 간 기능 개선용 식품조성물에 관한 것이다.The present invention relates to a food composition for relieving hangover and improving liver function, comprising an ice plant extract, a lard extract, and a mugwort extract.

회식 및 각종 모임을 통해 이루어지는 기존의 모습과 달리 코로나 시대를 통하여 혼술, 홈술 등의 새로운 개념의 음주 문화가 나타나게 되었다. 이러한 문화로 인하여 알코올의 판매량은 꾸준히 늘어나고 있다. 또한, 미국 캘리포니아주 샌프란시스코에 소재한 시장조사·컨설팅기관 그랜드 뷰 리서치 (Grand View Research)는 21일 공개한 '제품별, 공급경로별, 지역별, 영역별 숙취해소제 시장규모, 마켓셰어 및 트렌드 분석과 2021~2028년 전망'보고서에 따르면, 숙취해소제 시장은 계속되는 규모 증가로 2028년에는 46억 7,000만 달러의 규모를 형성할 것이라고 예상하였다. Unlike the existing appearances made through dinner parties and various gatherings, a new concept of drinking culture, such as drinking alone and drinking at home, has emerged through the Corona era. Due to this culture, sales of alcohol are steadily increasing. In addition, Grand View Research, a market research and consulting agency based in San Francisco, California, USA, announced on the 21st that 'hangover cure market size by product, supply route, region, and area, market share and trend analysis and According to the 2021-2028 Outlook report, the hangover cure market is expected to reach $4.67 billion in 2028 with continued growth.

숙취는 다량의 알코올 섭취 후 나타나는 증상으로, 두통, 설사, 식욕부진, 오심, 구토, 오한, 식은땀 등의 증상을 뜻하며, 객관적인 증상으로는 인식, 운동능력 저하, 혈액학적 변화 및 호르몬의 변화를 의미한다. 숙취의 원인은 탈수, 알코올 및 아세트알데히드, 포름알데히드, 아세톤과 같은 알코올 대사물의 독성, 흡수 장애에 의한 혈당, 비타민, 또는 무기질 등 영양소 결핍인 것으로 알려져 있다. A hangover is a symptom that appears after consuming a large amount of alcohol. It refers to symptoms such as headache, diarrhea, anorexia, nausea, vomiting, chills, and cold sweat. it means. It is known that the cause of a hangover is dehydration, toxicity of alcohol and alcohol metabolites such as acetaldehyde, formaldehyde, and acetone, and deficiency of nutrients such as blood sugar, vitamins, or minerals due to malabsorption.

음주 후 알코올은 3가지 경로를 통해 대사된다. 에탄올의 농도가 낮을 때는 위장관 또는 간에 존재하는 알코올 탈수소효소 (Alcohol dehydrogenase)와 아세트알데히드와 아세트산으로 대사되며, 이후 퍼옥시좀 (peroxisome)에 존재하는 카탈라제 (catalase)의 작용 등을 거쳐 이산화탄소와 물로 최종분해된다. 적당량 이상의 알코올이 유입되면 상기 기술한 대사체계의 균형이 파괴되어 생체 항상성을 유지하지 못하게 되어 단기적으로는 두통 또는 두중감, 집중력 감퇴, 속쓰림 및 소화불량 등이 초래되고 장기적으로는 간 기능 장애가 발생할 수 있다. 따라서 숙취를 해소 및 간 기능을 보호할 수 있는 숙취제거제는 계속해서 연구되고 있는 실정이다. After drinking, alcohol is metabolized through three pathways. When the concentration of ethanol is low, it is metabolized into alcohol dehydrogenase, acetaldehyde and acetic acid present in the gastrointestinal tract or liver, and then through the action of catalase present in the peroxisome to carbon dioxide and water. It breaks down. If more than an appropriate amount of alcohol is introduced, the balance of the metabolic system described above is destroyed, and body homeostasis cannot be maintained, resulting in headaches or heaviness, loss of concentration, heartburn and indigestion in the short term, and liver dysfunction in the long term. there is. Therefore, a hangover remover capable of relieving hangover and protecting liver function is being continuously studied.

대한민국 등록특허공보 제10-0574097호 (2006.04.27)Republic of Korea Patent Registration No. 10-0574097 (2006.04.27)

본 발명의 일 양상은 아이스플랜트 (Mesembryanthemum crystalinum) 추출물, 갈화 (Pueraria lobata flower) 추출물, 및 쑥 (Artemisia indica) 추출물을 포함하는 숙취해소 또는 간 기능 개선용 식품조성물을 제공하는 것이다.One aspect of the present invention is to provide a food composition for relieving hangover or improving liver function, comprising an ice plant ( Mesembryanthemum crystalinum ) extract, a gall flower ( Pueraria lobata flower) extract, and a mugwort ( Artemisia indica ) extract.

본 발명의 일 양상은 아이스플랜트 (Mesembryanthemum crystalinum) 추출물, 갈화 (Pueraria lobata flower) 추출물, 및 쑥 (Artemisia indica) 추출물을 포함하는 숙취해소 또는 간 기능 개선용 식품조성물을 제공한다.One aspect of the present invention provides a food composition for relieving hangover or improving liver function, comprising an ice plant ( Mesembryanthemum crystalinum ) extract, a gall flower ( Pueraria lobata flower ) extract, and a mugwort ( Artemisia indica ) extract.

상기 아이스플랜트 (Mesembryanthemum crystalinum)는 메셈브리안테맘속 다육식물로, 남아프리카의 나미브 사막에서 주로 서식한다.The ice plant ( Mesembryanthemum crystalinum ) is a succulent plant of the genus Mesembryanthemum, and lives mainly in the Namib Desert of South Africa.

상기 갈화 (Pueraria lobata flower)는 칡의 꽃을 의미하는 것으로, '계제', '녹곽', '황근'으로도 일컬어진다. The galhwa ( Pueraria lobata flower) means the flower of kudzu, and is also referred to as 'gyeje', 'nokgwak', and 'hwanggeun'.

상기 쑥 (Artemisia indica)은 국화과에 속하는 다년생초의 하나이다.
상기 쑥은 학명이 Artemisia indica인 쑥일 수 있다.
The mugwort ( Artemisia indica ) is one of the perennial plants belonging to Asteraceae.
The mugwort may be mugwort whose scientific name is Artemisia indica .

일 구체예에 따르면, 상기 아이스플랜트 추출물, 갈화 추출물, 및 쑥 추출물의 중량비는 1:2:2 내지 1:4:4 일 수 있다. 예를 들면, 상기 아이스플랜트 추출물, 갈화 추출물, 및 쑥 추출물의 중량비는 1:3:3일 수 있다. According to one embodiment, the weight ratio of the ice plant extract, the brown flower extract, and the mugwort extract may be 1:2:2 to 1:4:4. For example, the weight ratio of the ice plant extract, the brown flower extract, and the mugwort extract may be 1:3:3.

일 구체예에 따르면, 상기 추출물은 각각 독립적으로 물, 탄소수 1 내지 4의 저급 알코올 또는 이들의 혼합 용매로 추출한 것일 수 있다. 예를 들면, 물로 추출한 것일 수 있다.According to one embodiment, the extract may be independently extracted with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. For example, it may be extracted with water.

상기 추출물은 당업계에서 본 발명의 아이스플랜트 추출물, 갈화 추출물, 및 쑥 추출물을 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The extract may be prepared in a powder state by an additional process such as distillation under reduced pressure and freeze-drying or spray-drying the ice plant extract, lard extract, and mugwort extract of the present invention in the art.

상기 숙취는 다량의 알코올 섭취 후 나타나는 증상으로, 두통, 설사, 식욕부진, 오심, 구토, 오한, 식은땀 등의 증상을 뜻하며, 객관적인 증상으로는 인식 저하, 운동능력 저하, 혈액학적 변화 및 호르몬의 변화를 의미하는 것일 수 있다.The hangover is a symptom that appears after consuming a large amount of alcohol, and refers to symptoms such as headache, diarrhea, anorexia, nausea, vomiting, chills, cold sweat, etc. It could mean change.

상기 숙취해소는 두통, 설사, 식욕부진, 오심, 구토, 오한, 식은땀 등의 증상 또는 인식 저하, 운동능력 저하, 혈액학적 변화 및 호르몬의 변화의 증상을 완화하는 것일 수 있다. The hangover relief may be to alleviate symptoms such as headache, diarrhea, anorexia, nausea, vomiting, chills, cold sweat, or symptoms of cognitive decline, decreased exercise capacity, hematological changes and hormonal changes.

상기 숙취해소는 상기 아이스플랜트 추출물, 갈화 추출물, 및 쑥 추출물을 포함하는 조성물이 ADH 및 ALDH 활성을 증가시키므로 알코올 대사가 빠르게 진행되는 과정을 통해서 나타나는 것일 수 있다. The hangover relief may occur through a process in which alcohol metabolism is rapidly progressed because the composition including the ice plant extract, the gall flower extract, and the mugwort extract increases ADH and ALDH activities.

상기 간 기능 개선은 알코올로 인한 간세포 파괴를 억제하는 것일 수 있고, 알코올로 인하여 간 기능이 저하되는 것을 억제하는 것일 수 있다. The improvement of liver function may be suppression of liver cell destruction due to alcohol, or suppression of liver function deterioration due to alcohol.

일 구체예에 따르면, 상기 식품은 음료, 환, 정제, 캡슐, 젤리, 발효유, 캔디, 아이스크림 형태일 수 있다. According to one embodiment, the food may be in the form of a beverage, pill, tablet, capsule, jelly, fermented milk, candy, or ice cream.

본 발명의 조성물이 식품조성물로 제조되는 경우, 유효성분으로써 아이스플랜트 추출물, 갈화 추출물, 및 쑥 추출물 외에, 식품 제조 시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함할 수 있다. 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어, 말토오스, 수크로오스, 올리고당 등; 및 폴리사카라이드, 예를 들어, 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜일 수 있다. 향미제로서 천연 향미제[타우마틴, 스테비아 추출물(예를 들어, 레바우디오시드 A, 글리시르히진 등)] 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다.When the composition of the present invention is prepared as a food composition, in addition to the ice plant extract, the brown flower extract, and the mugwort extract, as active ingredients, it may include ingredients commonly added during food preparation, for example, proteins, carbohydrates, It may contain fats, nutrients, seasonings and flavors. Examples of carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose, oligosaccharides and the like; and polysaccharides, for example, conventional sugars such as dextrins and cyclodextrins, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents, natural flavoring agents (thaumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.

예를 들어, 본 발명의 식품조성물이 드링크제로 제조되는 경우에는 본 발명의 아이스플랜트 추출물, 갈화 추출물, 및 쑥 추출물 외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액 및/또는 감초 추출액 등이 추가로 포함될 수 있다.For example, when the food composition of the present invention is prepared as a drink, citric acid, high fructose corn syrup, sugar, glucose, acetic acid, malic acid, fruit juice, Eucommia extract, jujube extract, in addition to the ice plant extract, lard extract, and mugwort extract of the present invention And / or licorice extract and the like may be further included.

또한, 본 발명의 식품조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. In addition, the food composition of the present invention is various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and It may contain salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, and the like.

이러한 성분은 독립적으로 또는 조합하여 사용할 수 있으며, 이러한 첨가제의 비율은 본 발명의 식품조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택될 수 있으나, 이에 한정되는 것은 아니다.These components may be used independently or in combination, and the ratio of these additives may be selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the food composition of the present invention, but is not limited thereto.

본 발명의 아이스플랜트 추출물, 갈화 추출물, 및 쑥 추출물을 포함하는 식품조성물을 섭취하면 알코올 대사를 촉진시키고, 알코올로부터 간세포를 보호하므로 숙취를 억제하고 및 간 기능을 보호하는 효과가 있다.Ingestion of the food composition containing the ice plant extract, lard extract, and mugwort extract of the present invention promotes alcohol metabolism and protects liver cells from alcohol, thereby suppressing hangover and protecting liver function.

본 발명의 도면에서 N.A (Normal administered)) 또는 Control은 대조(무처리) 그룹, Alcohol은 에탄올 3g/kg 투여 그룹, GSH-YE는 에탄올 3g/kg 및 GSH-YE (글루타치온이 풍부한 효모추출물) 70mg/kg 투여 그룹, M. crystallinum은 에탄올 3g/kg 및 아이스플랜트 추출물 70mg/kg 투여 그룹, P. lobata flower은 에탄올 3g/kg 및 갈화 추출물 70mg/kg 투여 그룹, A.indica는 에탄올 3g/kg 및 쑥 추출물 70mg/kg 투여 그룹, 및 HEM(Herbal extract mixture)은 에탄올 3g/kg 및 아이스플랜트 추출물, 갈화 추출물, 및 쑥 추출물의 혼합물 70mg/kg 투여 그룹을 의미하는 것이다.
도 1은 각 그룹의 ADH (a) 및 ALDH (b) 활성을 확인하여 나타낸 그래프이다.
도 2는 각 그룹의 농도에 따른 레디컬 소거 활성을 확인하여 나타낸 그래프이다.
도 3은 아이스플랜트 추출물(M. crystallinum), 갈화 추출물 (P. lobata flower), 및 쑥 추출물 (A. indica)의 GABA 함량을 확인한 실험 데이터이다.
도 4는 각 그룹의 혈청 내 에탄올 농도를 0, 0.5, 1, 3, 5 시간에서 측정하여 나타낸 그래프 (a)와 혈청 내 알코올 농도 시간 곡선 값인 AUC를 계산하여 나타낸 그래프 (b)이다.
도 5는 각 그룹의 혈청 내 아세트알데히드 농도를 0, 0.5, 1, 3, 5 시간에서 측정하여 나타낸 그래프 (a)와 혈청 내 아세트알데히드 농도 시간 곡선 값인 AUC를 계산하여 나타낸 그래프 (b)이다.
도 6은 각 그룹의 ADH 효소 활성 (a), ALDH 효소 활성 (b), SOD 효소 활성 (c), GPx 효소 활성 (d)을 나타낸 데이터이다.
도 7은 각 그룹의 간세포 유전자 발현을 확인한 데이터로, 대사능력을 나타내는 ADH4, ADH6, ALDH2 유전자와 항산화 능력을 나타내는 GPX2, CYP2E1 유전자 발현량을 확인한 데이터이다.
도 8은 각 그룹에서 간 손상을 나타내는 유전자 지표인 TGF-β, SMAD-4, 및 α-SMA 발현량을 확인한 데이터이다.
In the drawings of the present invention, NA (Normal administered) or Control is the control (untreated) group, Alcohol is the ethanol 3g/kg administration group, GSH-YE is ethanol 3g/kg and GSH-YE (yeast extract rich in glutathione) 70mg /kg administration group, M. crystallinum ethanol 3g/kg and ice plant extract 70mg/kg administration group, P. lobata flower ethanol 3g/kg and brown flower extract 70mg/kg administration group, A.indica ethanol 3g/kg and The mugwort extract 70mg/kg administration group and HEM (Herbal extract mixture) mean the ethanol 3g/kg and ice plant extract, brown flower extract, and mugwort extract mixture 70mg/kg administration group.
1 is a graph showing the ADH (a) and ALDH (b) activities of each group.
2 is a graph showing the radical scavenging activity according to the concentration of each group.
Figure 3 is the experimental data confirming the GABA content of the ice plant extract ( M. crystallinum ), brown flower extract ( P. lobata flower), and mugwort extract ( A. indica ).
Figure 4 is a graph (a) showing the measured serum ethanol concentration of each group at 0, 0.5, 1, 3, and 5 hours, and a graph (b) showing the calculated AUC, which is the value of the serum alcohol concentration time curve.
5 is a graph (a) showing the concentration of acetaldehyde in the serum of each group measured at 0, 0.5, 1, 3, and 5 hours, and a graph (b) showing the calculated AUC, which is the value of the time curve of the acetaldehyde concentration in the serum.
6 is data showing ADH enzyme activity (a), ALDH enzyme activity (b), SOD enzyme activity (c), and GPx enzyme activity (d) of each group.
7 is data confirming the expression of hepatocyte genes in each group, and data confirming the expression levels of ADH4, ADH6, and ALDH2 genes representing metabolic abilities and GPX2 and CYP2E1 genes representing antioxidant capabilities.
8 is data confirming the expression levels of TGF-β, SMAD-4, and α-SMA, which are genetic indicators indicating liver damage, in each group.

이하 하나 이상의 구체예를 실시예를 통하여 보다 상세하게 설명한다. 그러나, 이들 실시예는 하나 이상의 구체예를 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, one or more specific examples will be described in more detail through examples. However, these examples are intended to illustrate one or more specific examples, and the scope of the present invention is not limited to these examples.

실시예 1: 실험 과정Example 1: Experimental procedure

1-1. 시약 준비 및 사용장비 1-1. Reagent preparation and equipment

AHD, ALDH 및 아스코르브산, 2,2-디페닐-1-피크릴히드라질 (2,2-diphenyl-1-picrylhydrazyl), 및 GABA는 시그마알드리치 (Sigma Aldrich)로부터 구매하였다. 아미노산 혼합 표준 용액 (type H)는 와코 퓨어 케미컬 인더스트리즈 (Wako Pure Chemical Industries, Ltd.)에서 구매하였다. 가시 검출기가 장착된 아미노산 분석기 (L-8900 시스템: Hitachi Inc)로 GABA 분석을 하였다. 실험에는 S9 래트 간 균질화효소 (MOLTOX Co) 혈청 ADH, ALDH, SOD, 및 글루타티온 과산화 효소 (glutathione peroxidase) ELISA 키트 (Cayman Chemical)를 사용하였다. 글루타티온이 풍부한 효모 추출물은 저지앙 센요 바이오테크 (Zhe-jiang Senyo Biotech, Huzhou City, China)에서 구매하였다. AHD, ALDH and ascorbic acid, 2,2-diphenyl-1-picrylhydrazyl, and GABA were purchased from Sigma Aldrich. Amino acid mixed standard solution (type H) was purchased from Wako Pure Chemical Industries, Ltd. GABA analysis was performed with an amino acid analyzer equipped with a visible detector (L-8900 system: Hitachi Inc). In the experiment, S9 rat liver homogenase (MOLTOX Co) serum ADH, ALDH, SOD, and glutathione peroxidase ELISA kit (Cayman Chemical) were used. Yeast extract rich in glutathione was purchased from Zhe-jiang Senyo Biotech (Huzhou City, China).

1-2. 허브 추출물 및 HEM (Herbal extract mixture) 준비 1-2. Preparation of herbal extracts and HEM (Herbal extract mixture)

건조된 아이스플랜트 (Mesembryanthemum crystalinum), 갈화 (Pueraria lobata flower), 및 쑥 (Artemisia indica)을 휴먼허브(humanherb, Daegu, Korea)에서 구입하여, 각각의 허브 (아이스플랜트, 갈화, 쑥)를 90℃에서 6시간동안 물 약 10배 중량 이상으로 추출하였다. 얻어진 추출물을 회전식 진공증발기에서 55 내지 65°Bx로 12~24시간 농축하므로, 아이스플랜트 추출물, 갈화 추출물, 및 쑥 추출물을 준비하였다. Dried ice plant ( Mesembryanthemum crystalinum ), brown flower ( Pueraria lobata flower), and mugwort ( Artemisia indica ) were purchased from Human Herb (Humanherb, Daegu, Korea), and each herb (ice plant, brown flower, mugwort) was incubated at 90 ° C. was extracted with about 10 times the weight of water or more for 6 hours. Since the obtained extract was concentrated in a rotary vacuum evaporator at 55 to 65 ° Bx for 12 to 24 hours, an ice plant extract, a brown flower extract, and a mugwort extract were prepared.

HEM (Herbal extract mixture)은 상기 아이스플랜트 추출물, 갈화 추출물, 및 쑥 추출물을 1:3:3 비율로 혼합하였다. 농축된 물질들은 실험을 위하여 물에 다시 용해하여 사용하였다. HEM (Herbal extract mixture) was a mixture of the ice plant extract, lard extract, and mugwort extract in a ratio of 1:3:3. Concentrated materials were used after being dissolved in water again for the experiment.

1-3. 유기산과 플라보노이드의 HPLC 분석1-3. HPLC analysis of organic acids and flavonoids

HEM의 유기산 및 플라보노이드는 UV 검출기가 장착된 Agilent 1280 HPLC 시스템 (agilent Technologies, St. Louis, MO, USA)을 사용하여 측정하였다. 플라보노이드의 크로마토그래피 분리는 CAPCEL PAC C18 UG120 (4.6×250 mm, 5 μm, SHISEIDO)을 사용하여 분석되었다. Alltech permous OA column은 540 nm 파장에서 말산, 말레인산, 숙신산, 아세트산, 프로피온산을 분석하기 위하여 사용하였으며, Bio-rad Aminex HPx-87H column은 210 nm 파장에서 부티르산과 타르타르산을 분석하기 위하여 사용하였다. 플라보노이드는 370 nm 파장에서 검출하였으며, 이동상으로는 25 mM 포스페이트 버퍼를 올텍 프루프 OA column으로 사용하였으며, 0.01 N 황산용액은 Bo-rad Aminex HPX-87H column으로 사용하였다. 플라보노이드 분석 이동상은 아세토니트릴(용매 A)의 인산 0.1%, 물 (용매 B)의 인산 0.1%로 구성하였으며, 모든 이동 유량은 1mL/min으로 설정하였다. Organic acids and flavonoids of HEM were measured using an Agilent 1280 HPLC system (agilent Technologies, St. Louis, MO, USA) equipped with a UV detector. Chromatographic separation of flavonoids was analyzed using a CAPCEL PAC C18 UG120 (4.6×250 mm, 5 μm, SHISEIDO). The Alltech permous OA column was used to analyze malic acid, maleic acid, succinic acid, acetic acid, and propionic acid at a wavelength of 540 nm, and the Bio-rad Aminex HPx-87H column was used to analyze butyric acid and tartaric acid at a wavelength of 210 nm. Flavonoids were detected at a wavelength of 370 nm, 25 mM phosphate buffer was used as a mobile phase for an Alltech proof OA column, and 0.01 N sulfuric acid solution was used for a Bo-rad Aminex HPX-87H column. The flavonoid analysis mobile phase consisted of 0.1% phosphoric acid in acetonitrile (solvent A) and 0.1% phosphoric acid in water (solvent B), and all mobile phases were set at 1 mL/min.

1-4. 아미노산 분석기의 크로마토그래피 방법 1-4. Chromatographic methods for amino acid analyzers

GABA 분석을 위하여 가시 검출기가 장착된 아미노산 분석기 (L-8900 시스템, Hitachi)를 사용하였다. 샘플 0.2 g을 15 ml의 시험튜브에 6 M HCl 3ml와 완전히 혼합하여 밀봉하였다. 상기 혼합물은 히팅 블록 (Heating block, Thermo-Fisher Scientific Co., Rockford, IL, USA)에서 110℃로 24시간동안 산 가수분해 (acid hydrolysis)를 실시하였다. For GABA analysis, an amino acid analyzer (L-8900 system, Hitachi) equipped with a visible detector was used. 0.2 g of the sample was thoroughly mixed with 3 ml of 6 M HCl in a 15 ml test tube and sealed. The mixture was subjected to acid hydrolysis at 110° C. for 24 hours in a heating block (Thermo-Fisher Scientific Co., Rockford, IL, USA).

가수분해된 시료 10 μl와 나트륨 희석 완충액 (pH 2.2) 990 μl를 혼합한 후 0.22 μm 멤브레인 필터를 통하여 여과하였다. GABA와 글루탐산염의 함량은 피크 면적을 계산하여 구하였으며, 이는 표준 용액과 비교하였다. After mixing 10 μl of the hydrolyzed sample with 990 μl of sodium dilution buffer (pH 2.2), it was filtered through a 0.22 μm membrane filter. The contents of GABA and glutamate were obtained by calculating peak areas, which were compared with standard solutions.

1-5. ADH (Alcohol dehydrogenase) 및 ALDH (Acetaldehyde dehydrogenase) 활성화 측정1-5. Measurement of ADH (alcohol dehydrogenase) and ALDH (acetaldehyde dehydrogenase) activation

ADH와 ALDH 활성화 측정은 논문 [Bostian et al. 1987] 에서 기재된 방법을 변형하여 사용하였으며, 흡광도 340 nm에서 NADH의 생성속도를 지표로 사용하였다. Measurements of ADH and ALDH activation were reported in a paper [Bostian et al. 1987] was modified and used, and the rate of NADH production at 340 nm absorbance was used as an indicator.

ADH 측정의 경우, 증류수 1.4 ml를 1.0 M tris-HCl 버퍼 (pH 8.8) 0.75 ml, 20mM NAD+ 0.3 ml, 에탄올 0.3 ml, 소 혈청 알부민 0.1%에서 유화한 S9 SD 래트 간 균질산염 0.1 ml, 0.15 ml 샘플을 최대 3 ml 큐벳(cuvette)에서 혼합하였다. 상기 용액은 5분간 배양한 후, 340 nm에서 측정하였다. For ADH measurement, 0.1 ml, 0.15 ml of S9 SD rat liver homogenate emulsified in 1.4 ml of distilled water in 0.75 ml of 1.0 M tris-HCl buffer (pH 8.8), 0.3 ml of 20 mM NAD+, 0.3 ml of ethanol, 0.1% bovine serum albumin Samples were mixed in a maximum 3 ml cuvette. The solution was incubated for 5 minutes and then measured at 340 nm.

ALDH 측정의 경우, 증류수 2.1 ml, 1.0 M tris-HCl 버퍼 (pH 8.0), 20nm NAD+ 0.1 ml, 0.33 M 2-메르캅토에탄올 0.1 ml, S9SD 래트 간 균질산염 0.1 ml, 샘플 0.1 ml를 혼합하여 측정하였다. 상기 샘플로는 대조군으로 무처리군, 글루타치온이 풍부한 효모추출물 (GSH-YE), 아이스플랜트 추출물, 갈화 추출물, 쑥 추출물, 및 아이스플랜트, 갈화, 및 쑥 추출물의 혼합물 (HEM)을 사용하였다. For ALDH measurement, 2.1 ml of distilled water, 1.0 M tris-HCl buffer (pH 8.0), 0.1 ml of 20nm NAD+, 0.1 ml of 0.33 M 2-mercaptoethanol, 0.1 ml of S9SD rat liver homogenate, and 0.1 ml of sample were measured. did As the samples, untreated group, glutathione-rich yeast extract (GSH-YE), ice plant extract, brown flower extract, mugwort extract, and a mixture of ice plant, brown flower, and mugwort extract (HEM) were used as the control group.

1-6. DPPH 레니컬 소거 활성 (DPPH radical scavenging activity) 측정1-6. Measurement of DPPH radical scavenging activity

DPPH 0.36 mM인 에탄올 용액을 제조하고 동일한 부피의 샘플을 혼합하였다. An ethanol solution with DPPH of 0.36 mM was prepared and equal volumes of samples were mixed.

상기 혼합용액은 45분동안 배양한 후 517 nm에서 측정하였다. 상기 샘플로는 아스코르브산을 대조군으로 사용하였으며, GSH-YE, 및 각 추출물, 및 HEM을 사용하였다. The mixed solution was incubated for 45 minutes and then measured at 517 nm. As the sample, ascorbic acid was used as a control, and GSH-YE, each extract, and HEM were used.

DPPH 소거 활성은 다음과 같은 식 1을 이용하여 계산되었다. DPPH scavenging activity was calculated using Equation 1 as follows.

[식 1][Equation 1]

DPPH 래디컬 소거 활성 (%)= {Abscontrol - (Abssample - Abssample blank)}/ Abscontrol ×100DPPH radical scavenging activity (%) = {Abs control - ( Abs sample - Abs sample blank) }/ Abs control ×100

1-7. 동물 1-7. animal

SD래트 (수컷, 7주령, 200-250g)는 DBL(대한민국)에서 구입하여 사용하였다. 상기 래트는 20~23℃, 12시간 명암주기의 환경을 제공하는 실험실에 수용하였으며, 고압살균된 표준 실험실 식단을 먹였으며, 물에 자유롭게 접근할 수 있도록 하였다. 보든 실험 절차는 CHAON 윤리심사위원회 (CE2128)에 의하여 승인되었다. SD rats (male, 7 weeks old, 200-250 g) were purchased from DBL (Korea) and used. The rats were housed in a laboratory provided with an environment of 20-23° C. and a 12-hour light/dark cycle, were fed a standard autoclaved laboratory diet, and had free access to water. Borden experimental procedures were approved by the CHAON Ethics Review Board (CE2128).

1-8. 약물 동태 연구1-8. Pharmacokinetic studies

약동학에 대한 프로토콜은 기존에 알려진 방법에서 약간 수정하여 수행하였다. 간단히, 수컷 SD 래트를 하기 표 1과 같이 무작위로 8 마리씩 4개의 그룹으로 나누었다. 래트는 GSH-YE 또는 HEM을 투여한 후 30분 후에 3 g/kg의 에탄올을 경구로 투여하였다. HEM은 아이스플랜트 추출물, 갈화 추출물, 및 쑥 추출물을 1:3:3의 비율로 혼합하여 구성된 것이며, 최종농도는 70mg/kg이었다. 혈액 샘플은 투여 후, 0, 0.5, 1, 3, 5시간 후 래트의 경정맥을 통하여 채취한 뒤 3000 g에서 30분간 원심분리하여 혈청을 분리하였다. 분리한 혈청을 하기와 같은 방법으로 분석하므로 약물의 동태를 연구하였다.The protocol for pharmacokinetics was performed by slightly modifying the previously known method. Briefly, male SD rats were randomly divided into 4 groups of 8 rats as shown in Table 1 below. Rats were orally administered 3 g/kg of ethanol 30 minutes after administration of GSH-YE or HEM. HEM was composed of a mixture of ice plant extract, brown flower extract, and mugwort extract in a ratio of 1:3:3, and the final concentration was 70 mg/kg. Blood samples were collected through the jugular vein of rats 0, 0.5, 1, 3, and 5 hours after administration, and then centrifuged at 3000 g for 30 minutes to separate serum. The kinetics of the drug were studied by analyzing the separated serum in the following manner.

그룹명칭group name 투여 내용Dosage content 대조그룹control group 무처리untreated 알코올 그룹alcohol group 에탄올 3 g/kg 투여Ethanol 3 g/kg administration GSH-YE 그룹GSH-YE Group 에탄올 3 g/kg 및 GSH-YE 70 mg/kg 투여Ethanol 3 g/kg and GSH-YE 70 mg/kg administered HEM 그룹HEM group 에탄올 3 g/kg 및 HEM 70 mg/kg 투여Ethanol 3 g/kg and HEM 70 mg/kg administered

1-8-1. 혈액 내 알코올 농도, 아세트알데히드 농도측정1-8-1. Measurement of alcohol concentration and acetaldehyde concentration in blood

혈중 알코올 농도는 alcohol 측정용 kit(#332-UV, Sigma Chemical Co., St. Louis, USA)를 이용하여 측정하였다. 10 ul의 혈청과 3 ml의 NAD-ADH 용액을 섞은 후 30℃ 에서 10분간 incubation 시켜 파장 340 nm에서 생성된 NADH의 농도에 따른 흡광도의 변화를 측정하였다. 이때 혈액의 알코올 농도(g/L)는 표준용액을 이용하여 계산하였다. 혈액 중 아세트알데히드 농도는 아세트알데히드가 ALDH에 의해 acetate를 생성하고 NAD+의 존재 하에 NADH를 생성하는데, 생성된 NADH의 농도를 파장 340 nm에서 측정하는 원리로 제조된 kit(Roche Co., USA)를 사용하여 측정하였다.Blood alcohol concentration was measured using an alcohol measurement kit (#332-UV, Sigma Chemical Co., St. Louis, USA). After mixing 10 ul of serum and 3 ml of NAD-ADH solution, incubation was performed at 30° C. for 10 minutes, and the change in absorbance according to the concentration of NADH generated at a wavelength of 340 nm was measured. At this time, the blood alcohol concentration (g/L) was calculated using a standard solution. The concentration of acetaldehyde in the blood is measured by a kit (Roche Co., USA) manufactured on the principle that acetaldehyde generates acetate by ALDH and NADH is produced in the presence of NAD+, and the concentration of generated NADH is measured at a wavelength of 340 nm. It was measured using

1-8-2. 혈액 내 알코올탈수소효소(ADH) 및 알데히드탈수소효소(ALDH) 농도측정1-8-2. Measurement of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) concentrations in the blood

혈액 중의 알코올탈수소효소(ADH)와 아세트알데히드탈수소효소 (ALDH) 효소 활성은 Biovision (Milpitas, CA, USA)사로부터 구입한 alcohol dehydrogenase activity assay kit와 aldehyde dehydrogenase activity assay kit를 이용하여 제조사에서 제시한 방법에 따라 분리된 혈청으로부터 측정하였다.Alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) enzyme activities in the blood were measured using the alcohol dehydrogenase activity assay kit and aldehyde dehydrogenase activity assay kit purchased from Biovision (Milpitas, CA, USA), as suggested by the manufacturer. It was measured from serum separated according to.

1-8-3. 혈액 내 SOD 및 GPx 활성 측정1-8-3. Measurement of SOD and GPx activity in blood

항산화 효소인 SOD 활성 및 GPx 활성은 colorimetry 검사법을 사용하여 측정하였다. SOD 활성 측정은 Superoxide Dismutase assay Kit (#706002, Cayman chemical company, Michigan, USA)를 사용하여 제조사의 지시에 따라 실험하였며, 450nm에서 측정하였다. GPx 활성 측정은 Glutathione Peroxidase Assay Kit (#703102, Cayman chemical company, Michigan, USA)를 사용하여 제조사의 지시에 따라 실험하였으며, 340nm에서 측정하였다. SOD activity and GPx activity, which are antioxidant enzymes, were measured using a colorimetry assay. SOD activity was measured using the Superoxide Dismutase assay Kit (#706002, Cayman chemical company, Michigan, USA) according to the manufacturer's instructions, and was measured at 450 nm. GPx activity was measured using Glutathione Peroxidase Assay Kit (#703102, Cayman chemical company, Michigan, USA) according to the manufacturer's instructions, and was measured at 340 nm.

1-9. 간 및 폐 조직에서의 유전자 발현 분석1-9. Gene expression analysis in liver and lung tissues

총 RNA는 Easy-spinTM RNA 키트의 프로토콜을 사용하여 추출하였다. 간 조직 검체는 Fast-prep®-24의 용해 완충액을 사용하여 매트릭스 D 튜브에서 균질화하였다. 조직을 분쇄한 후 Easy-spinTM RNA 키트의 나머지 프로토콜을 따랐습니다. 총 RNA는 후속 유전자 발현 분석을 위하여 -70℃에 저장하였다. 총 RNA는 Omniscript® RT 키트를 사용하여 cDNA로 역전사하였다. cDNA는 Quant StudioTM 6 Flex Real-Time instrument에서 Gene Expression Master Mix 및 TaqMan Probe로 증폭되었다. 정량화는 Taqman primer, ADH4(Rn00568609_m1), ADH6(Rn01522017_s1), ALDH2(Rn00583474_m1), GPX2(Rn00822100_GH), CYP2E1(Rn00580624_m1), GAPDH(Rn01775736_g1), TGF-β(Rn00572010_m1), SMAD-4(Rn00570593_m1), α-smooth muscle actin (α -SMA, Rn01759928_g1) 를 사용하여 수행하였다.Total RNA was extracted using the protocol of the Easy-spin TM RNA kit. Liver tissue samples were homogenized in Matrix D tubes using Fast-prep®-24 lysis buffer. After the tissue was minced, the rest of the protocol from the Easy-spin TM RNA kit was followed. Total RNA was stored at -70°C for subsequent gene expression analysis. Total RNA was reverse transcribed into cDNA using the Omniscript® RT kit. cDNA was amplified with Gene Expression Master Mix and TaqMan Probe on a Quant Studio TM 6 Flex Real-Time instrument. 정량화는 Taqman primer, ADH4(Rn00568609_m1), ADH6(Rn01522017_s1), ALDH2(Rn00583474_m1), GPX2(Rn00822100_GH), CYP2E1(Rn00580624_m1), GAPDH(Rn01775736_g1), TGF-β(Rn00572010_m1), SMAD-4(Rn00570593_m1), α -smooth muscle actin (α -SMA, Rn01759928_g1) was used.

1-10. 통계분석1-10. statistical analysis

모든 데이터는 평균±표준 오차로 표시하였다. 유의한 차이는 일원 분산 분석을 사용하여 통계적으로 분석하였으며, 던컨의 다중 범위 검정 (p<0.05)이 뒤를 이었다. 얻어진 데이터는 GraphPad Prism 5 프로그램 (GraphPad Software, Inc.)을 이용하여 분석하였다. All data are expressed as mean ± standard error. Significant differences were statistically analyzed using one-way ANOVA followed by Duncan's multiple range test (p<0.05). The obtained data was analyzed using the GraphPad Prism 5 program (GraphPad Software, Inc.).

실시예 2: 실험 결과Example 2: Experimental results

2-1. 추출물 및 혼합물의 ADH 및 ALDH 활성 확인2-1. Determination of ADH and ALDH activities of extracts and mixtures

상기 실시예 1에서 준비한 허브 추출물의 ADH 및 ALDH 활성을 확인하고, ADH 및 ALDH 활성이 현저한 효과를 나타내는 비율을 찾기 위하여, 각 추출물을 혼합하여 ADH 및 ALDH 활성 확인 실험을 하였다. In order to confirm the ADH and ALDH activities of the herb extract prepared in Example 1, and to find a ratio showing a significant ADH and ALDH activity, ADH and ALDH activity confirmation experiments were performed by mixing each extract.

먼저 ADH 활성이 더 현저히 나타나는 갈화 추출물 및 쑥 추추물을 혼합하였을 때 시너지 효과를 나타내는지, 각 비율을 조절하였을 때 더 현저한 효과를 나타내는지 확인하였다. 그 결과, 하기 표 2에서 보이는 바와 같이, 갈화 추출물 및 쑥 추출물을 1:1로 혼합하였을 때가 다른 비율 대비 현저히 높은 수치의 효과를 나타내는 것을 확인하였다. 따라서 갈화 추출물 및 쑥 추출물의 혼합비율을 1:1로 확정하였다. First, it was confirmed whether a synergistic effect was exhibited when the brown flower extract and mugwort extract, which exhibited more marked ADH activity, were mixed, or a more pronounced effect was obtained when each ratio was adjusted. As a result, as shown in Table 2 below, it was confirmed that when the brown flower extract and the mugwort extract were mixed at a ratio of 1:1, the effect was significantly higher than that of other ratios. Therefore, the mixing ratio of the brown flower extract and the mugwort extract was determined to be 1:1.

그 후, 아이스플랜트 추출물과 상기 갈화 추출물 및 쑥 추출물의 최적의 비율을 확인하기 위하여, 하기 표 2에 나타난 비율로 혼합하고 ADH 및 ALDH 활성을 확인하였다. 그 결과, 하기 표 2에서 보이는 바와 같이, 갈화 추출물 및 쑥 추출물을 아이스플랜트 대비 3배 더 많이 혼합한 혼합물에서 ADH 활성 및 ALDH 활성이 현저히 증가하는 것을 확인하였다. 따라서 HEM의 아이스플랜트 추출물, 갈화 추출물, 및 쑥 추출물 비율은 1:3:3으로 확정하였다. Then, in order to confirm the optimal ratio of the ice plant extract, the brown flower extract and the mugwort extract, they were mixed in the ratio shown in Table 2 below, and the ADH and ALDH activities were confirmed. As a result, as shown in Table 2 below, it was confirmed that the ADH activity and the ALDH activity significantly increased in the mixture in which the brown flower extract and the mugwort extract were mixed 3 times more than the ice plant. Therefore, the ratio of the ice plant extract, the brown flower extract, and the mugwort extract of HEM was determined to be 1:3:3.

Figure 112022098362994-pat00001
Figure 112022098362994-pat00001

2-2. ADH 및 ALDH 활성의 시험관 내 분석2-2. In vitro assay of ADH and ALDH activity

천연 허브 추출물인 아이스플랜트 (M. crystalinum) 추출물, 갈화 (P. lobata flower) 추출물, 쑥 (A. indica) 추출물과 HEM 추출물의 ADH 및 ALDH 효소 활성에 미치는 영향을 확인하기 위하여 소 혈청 알부민 용액 0.1%를 포함한 S9 래트 간 균질산염을 사용하였다. Bovine serum albumin solution 0.1 % S9 rat liver homogenate was used.

도 1A에서 보이는 바와 같이, GSH-YE 그룹뿐만 아니라 천연 허브 추출물 처리 그룹들에서도 ADH 효소 활성이 개선되는 것을 확인하였다. 도 1B에서 보이는 바와 같이, 아이스플랜트 추출물은 다른 허브 추출물보다 현저히 향상되고, 양성대조군인 GSH-YE와 유사한 정도의 ALDH 활성 분석 결과를 나타내었다. 또한, 도 1에서 보이는 바와 같이, HEM은 ADH와 ALDH 활성에서 157.89±1.28%, 125.92±9.72%로 모두 시너지 효과를 나타내는 것을 확인하였다. As shown in Figure 1A, it was confirmed that the ADH enzyme activity was improved not only in the GSH-YE group but also in the natural herb extract treatment group. As shown in FIG. 1B, the ice plant extract was significantly improved than other herbal extracts, and showed the ALDH activity assay similar to that of the positive control, GSH-YE. In addition, as shown in FIG. 1, it was confirmed that HEM showed a synergistic effect in both ADH and ALDH activities by 157.89 ± 1.28% and 125.92 ± 9.72%.

2-3. DPPH 유리 레디컬 소거 활성 분석2-3. DPPH free radical scavenging activity assay

각 허브 추출물과 HEM의 항산화 효과를 확인하기 위하여, DPPH 유리 레디컬 소거활성을 측정하였다. In order to confirm the antioxidant effect of each herb extract and HEM, DPPH free radical scavenging activity was measured.

도 2에서 보이는 바와 같이, DPPH 유리 레디컬 소거 활성은 HEM과 쑥 추출물이 가장 현저한 효과를 가지고 있다는 것을 확인하였으며, 갈화 추출물, 쑥 추출물 및 HEM은 농도에 의존하여 항산화 효과가 나타난다는 것을 확인하였다. As shown in FIG. 2, it was confirmed that HEM and mugwort extract had the most significant effects on DPPH free radical scavenging activity, and that brown flower extract, mugwort extract, and HEM exhibited concentration-dependent antioxidant effects.

2-4. GABA 함량 분석2-4. GABA content analysis

아이스플랜트 추출물, 갈화 추출물, 쑥 추출물에 포함된 GABA를 자동 아미노산 분석기로 분석하였다. 도 3에서 보이는 바와 같이, 아이스플랜트 추출물의 GABA 함량은 3.02 ± 0.25 mg/g로, 갈화 추출물의 GABA 함량인 1.16 ± 0.11 mg/g 과 쑥 추출물의 GABA 함량인 0.92 ± 0.16 mg/g보다 현저히 높은 것을 확인하였다. GABA contained in ice plant extract, brown flower extract, and mugwort extract was analyzed using an automatic amino acid analyzer. As shown in Figure 3, the GABA content of the ice plant extract was 3.02 ± 0.25 mg / g, significantly higher than the GABA content of the brown flower extract of 1.16 ± 0.11 mg / g and the GABA content of the mugwort extract of 0.92 ± 0.16 mg / g. confirmed that

2-5. HEM, 유기산 및 플라보노이드, 아미노산 의 화학 성분 분석2-5. Chemical composition analysis of HEM, organic acids and flavonoids, amino acids

HEM에 포함된 화학성분, 유기산, 플라보노이드는 HPLC로 분석하였다. Chemical components, organic acids, and flavonoids contained in HEM were analyzed by HPLC.

측정된 유기산 함량은 하기 표 3에 나타내었으며, 플로보노이드 함량은 하기 표 4에 나타내었으며, 아미노산 (GABA) 함량은 하기 표 5에 나타내었다. HEM은 유기산에서 석신산 함량이 높았으며, 이는 쑥 추출물에서 가장 많은 양이 나타났다. 플라노이드에서는 퀘르세틴 (quercetin) 함량이 높았으며, 이는 갈화에서 가장 많은 양이 나타났다.The measured organic acid content is shown in Table 3 below, the flavonoid content is shown in Table 4 below, and the amino acid (GABA) content is shown in Table 5 below. HEM showed high content of succinic acid among organic acids, which was the highest in mugwort extract. In planoids, the content of quercetin was high, and the highest amount was found in brown rice.

Oranic acidOranic acid HEM (mg/g)HEM (mg/g) M. crystallinum
(mg/g)
M. crystallinum
(mg/g)
P. lobata flower
(mg/g)
P. lobata flower
(mg/g)
A. indica
(mg/g)
A. indica
(mg/g)
Malic acidMalic acid 9.38 ± 1.789.38 ± 1.78 20.44 ± 2.2920.44 ± 2.29 8.82 ± 1.718.82 ± 1.71 6.25 ± 1.806.25 ± 1.80 Maleic acidmaleic acid 0.09 ± 0.030.09 ± 0.03 0.06 ± 0.010.06 ± 0.01 0.13 ± 0.050.13 ± 0.05 0.07 ± 0.040.07 ± 0.04 Succinic acidSuccinic acid 30.49 ± 3.4830.49 ± 3.48 11.07 ± 0.0411.07 ± 0.04 5.27 ± 0.025.27 ± 0.02 62.19 ± 7.4862.19 ± 7.48 Acetic acid Acetic acid 13.91 ± 4.6313.91 ± 4.63 12.59 ± 3.6312.59 ± 3.63 17.54 ± 5.7217.54 ± 5.72 10.72 ± 3.1610.72 ± 3.16

FlavonoidFlavonoids HEM (mg/g)HEM (mg/g) M. crystallinum
(mg/g)
M. crystallinum
(mg/g)
P. lobata flower
(mg/g)
P. lobata flower
(mg/g)
A. indica
(mg/g)
A. indica
(mg/g)
QuercetinQuercetin 0.69 ± 0.090.69 ± 0.09 0.19 ± 0.080.19 ± 0.08 1.38 ± 0.241.38 ± 0.24 0.17 ± 0.090.17 ± 0.09 KaemferolKaemferol 0.27 ± 0.040.27 ± 0.04 NDND 0.62 ± 0.130.62 ± 0.13 ND (Non detected)ND (Non-detected) IsorhamnetinIsorhamnetin 0.09 ± 0.020.09 ± 0.02 0.05 ± 0.0010.05 ± 0.001 0.05. ± 0.020.05. ± 0.02 0.14 ± 0.070.14 ± 0.07

Amino acidAmino acids HEM (mg/g)HEM (mg/g) M. crystallinum
(mg/g)
M. crystallinum
(mg/g)
P. lobata flower
(mg/g)
P. lobata flower
(mg/g)
A. indica
(mg/g)
A. indica
(mg/g)
GABAGABA 0.69 ± 0.090.69 ± 0.09 0.19 ± 0.080.19 ± 0.08 1.38 ± 0.241.38 ± 0.24 0.17 ± 0.090.17 ± 0.09

2-6. HEM이 혈청 내 에탄올 농도에 미치는 영향 확인 2-6. Confirmation of the effect of HEM on the concentration of ethanol in serum

HEM이 에탄올 흡수를 억제하고 숙취 증상을 예방하는 효과가 있는지 확인하였다. It was confirmed whether HEM inhibits ethanol absorption and prevents hangover symptoms.

도 4에서 보이는 바와 같이, 각 그룹의 래트에서 에탄올 농도 변화를 확인하여 도 4A에 나타내었으며, 혈청 농도 시간 곡선 (AUC) 값 아래의 면적을 계산하여 도 4B에 나타내었다. 혈액은 래트에서 3 g/kg의 에탄올을 경구 투여한 후 5회, 0, 0.5, 1, 3, 5시간 동안 채취하였다. 모든 그룹에서 혈청 에탄올 농도는 0.5시간에서 최대 농도에 도달한 후 지속적으로 감소하였다. 도 4에서 보이는 바와 같이, HEM을 투여한 래트에서 혈청 내 에탄올 농도가 동시간 대비 가장 낮은 수치를 나타내는 것을 확인하였다. 또한, 하기 표 6에서 보이는 바와 같이, 알코올, GSH-YE, HEM 그룹에서 에탄올의 AUC 값은 각각 2.583 ± 0.541, 1.541 ± 0.465, 0.796 ± 0.188 g/L*h였다. HEM 투여 그룹에서 피크 혈청 에탄올 농도 (Cmax) 값이 알코올 그룹 대비 유의하게 감소하는 것을 확인하였다.As shown in FIG. 4, the change in ethanol concentration in rats of each group was confirmed and shown in FIG. 4A, and the area under the serum concentration time curve (AUC) value was calculated and shown in FIG. 4B. Blood was collected for 5 times, 0, 0.5, 1, 3, and 5 hours after oral administration of 3 g/kg of ethanol in rats. Serum ethanol concentration in all groups decreased continuously after reaching the maximum concentration at 0.5 hour. As shown in FIG. 4, it was confirmed that the serum ethanol concentration in rats administered with HEM was the lowest compared to the same time period. In addition, as shown in Table 6 below, the AUC values of ethanol in the alcohol, GSH-YE, and HEM groups were 2.583 ± 0.541, 1.541 ± 0.465, and 0.796 ± 0.188 g/L*h, respectively. It was confirmed that the peak serum ethanol concentration (Cmax) value in the HEM administration group decreased significantly compared to the alcohol group.

ParametersParameters AlcoholAlcohol GSH-YEGSH-YE HEMHEM AUC (g/L*h)AUC (g/L*h) 2.583 ± 0.5412.583 ± 0.541 1.541 ± 0.4651.541 ± 0.465 0.796 ± 0.1880.796 ± 0.188 Cmax (g/L)Cmax (g/L) 0.726 ± 0.1190.726 ± 0.119 0.439 ± 0.0790.439 ± 0.079 0.218 ± 0.0690.218 ± 0.069 Tmax (h)Tmax (h) 0.563 ± 0.1770.563 ± 0.177 0.562 ± 0.1760.562 ± 0.176 1.1 ± 0.6991.1±0.699

2-7. HEM이 혈청 내 아세트알데히드 농도에 미치는 영향 확인2-7. Confirmation of the effect of HEM on the concentration of acetaldehyde in serum

에탄올 투여 후 약 5회 혈청 내 아세트알데히드 농도를 확인하였으며, 상기 실시예 2-6과 같이, 0, 0.5, 1, 3, 5시간으로 채취하였다.After administration of ethanol, the concentration of acetaldehyde in serum was checked about 5 times, and as in Examples 2-6, it was collected at 0, 0.5, 1, 3, and 5 hours.

도 5에서 보이는 바와 같이, HEM을 투여한 래트에서 혈청 내 아세트알데이드 농도가 가장 낮았으며, HEM 투여한 래트의 경우에는 아세트알데이트의 혈청 내 농도가 0.1 g/L 를 초과하여 측정된 시간이 없는 것을 알 수 있었다. 아세트알데히드 약동학 파라미터 결과는 하기 표 7에 나타내었다. As shown in FIG. 5, the concentration of acetaldehyde in serum was the lowest in rats administered with HEM, and in the case of rats administered with HEM, the serum concentration of acetaldehyde exceeded 0.1 g/L, and the measured time was longer. found out that there was no Acetaldehyde pharmacokinetic parameter results are shown in Table 7 below.

ParametersParameters AlcoholAlcohol GSH-YEGSH-YE HEMHEM AUC (g/L*h)AUC (g/L*h) 1.003 ± 0.2141.003 ± 0.214 0.688 ± 0.0840.688 ± 0.084 0.457 ± 0.1570.457 ± 0.157 Cmax (g/L)Cmax (g/L) 0.341 ± 0.0860.341 ± 0.086 0.239 ± 0.0260.239 ± 0.026 0.125 ± 0.0430.125 ± 0.043 Tmax (h)Tmax (h) 0.563 ± 0.0020.563 ± 0.002 0.5 ± 0.1760.5 ± 0.176 1.3 ± 0.9181.3 ± 0.918

2-8. 알코올 대사 효소 (ADH 및 ALDH) 및 항산화 효소 (SOD 및 GPx) 활성 2-8. Alcohol metabolizing enzymes (ADH and ALDH) and antioxidant enzymes (SOD and GPx) activities

효소 활성에 대한 HEM 연구를 위하여, 알코올 대사 효소와 항산화 효소를 확인하였다. For HEM studies on enzyme activity, alcohol metabolizing enzymes and antioxidant enzymes were identified.

도 6A 및 도 6B에서 보이는 바와 같이, ADH 효소 및 ALDH 효소의 활성은 GSH-YE 그룹과 HEM 그룹이 Alcohol 그룹 대비 현저히 높은 것을 확인하였다. 구체적으로, ADH 효소 활성은 HEM 그룹에서 Alcohol 그룹 대비 약 1.75배, ALDH 효소 활성은 Alcohol 그룹보다 약 4.09배 현저히 높은 활성을 나타내는 것을 확인하였다.As shown in FIGS. 6A and 6B , it was confirmed that the activities of the ADH enzyme and the ALDH enzyme were significantly higher in the GSH-YE group and the HEM group than in the Alcohol group. Specifically, it was confirmed that the ADH enzyme activity in the HEM group was about 1.75 times higher than that of the Alcohol group, and the ALDH enzyme activity was about 4.09 times higher than that of the Alcohol group.

혈청 내 효소 활성은 도 6C, 도 6D 및 하기 표 8에서 나타난 바와 같이, Alcohol 그룹 대비 GSH-YE 그룹 및 HEM 그룹이 효소 활성이 높은 것을 확인하였으며, 대조그룹 (무처리 그룹)인 N.A 그룹과 유사한 수치를 나타내는 것을 확인하였다. 또한, HEM 그룹의 경우에는 N.A 그룹보다 더 높은 수치를 나타내므로, HEM이 SOD 및 GPx 효소를 더 활성화시킨다는 점을 확인하였다. As shown in Figures 6C, 6D and Table 8, the enzyme activity in the serum was confirmed to be higher in the GSH-YE group and the HEM group compared to the Alcohol group, similar to that of the N.A group, which is a control group (untreated group). It was confirmed that the numerical value was indicated. In addition, since the HEM group showed higher values than the N.A group, it was confirmed that HEM activates SOD and GPx enzymes more.

ParametersParameters N.A (Control)N.A. (Control) AlcoholAlcohol GSH-YEGSH-YE HEMHEM SOD (U/L)SOD (U/L) 10.12 ± 0.3410.12 ± 0.34 6.60 ± 0.826.60 ± 0.82 9.06 ± 1.719.06 ± 1.71 10.79 ± 2.4010.79 ± 2.40 GPx (U/L)GPx (U/L) 26.11±2.1526.11±2.15 14.04±4.1514.04±4.15 26.31±4.4926.31±4.49 27.46 ± 1.5127.46 ± 1.51

2-9. 간 세포 내 유전자 발현 분석 2-9. Analysis of gene expression in liver cells

래트의 간 조직에서 에탄올 투여에 대한 유전자 반응을 확인하였다. Gene responses to ethanol administration were confirmed in rat liver tissue.

대사능력은 ADH4, ADH6, ALDH2 유전자를 확인하였고, 항산화능력은 GPX2, CYP2E1 유전자를 확인하였다.ADH4, ADH6, and ALDH2 genes were confirmed for metabolic ability, and GPX2 and CYP2E1 genes were confirmed for antioxidant ability.

도 7 에서 보이는 바와 같이, AHD4, ADH6, ALDH2, GPX2 유전자는 무처리 그룹 대비 Alcohol 그룹에서 유전자 발현량이 감소하는 것을 확인하였으며, GSH-YE 그룹과 HEM 그룹에서는 오히려 무처리 그룹보다 증가하는 것을 확인하였다. 또한, 산화 스트레스 관련 유전자인 CYP2E1은 무처리 그룹 대비 Alcohol 그룹에서 유전자 발현량이 증가하였으며, GSH-YE 그룹 및 HEM 그룹이 Alcohol 그룹 대비 유전자 발현량이 감소하는 것을 확인하였다. As shown in Figure 7, it was confirmed that the gene expression levels of the AHD4, ADH6, ALDH2, and GPX2 genes decreased in the Alcohol group compared to the untreated group, and increased in the GSH-YE and HEM groups rather than the untreated group. . In addition, CYP2E1, an oxidative stress-related gene, increased in gene expression in the Alcohol group compared to the untreated group, and decreased gene expression in the GSH-YE and HEM groups compared to the Alcohol group.

또한, TGF-β/SMAD 신호 전달 경로와 α-SMA는 알코올에서 간 손상 및 염증을 유발시킬 수 있어, 상기 TGF-β/SMAD 신호 전달 경로와 α-SMA 억제 작용은 간 손상을 완화시킨다. In addition, since the TGF-β/SMAD signaling pathway and α-SMA can induce liver damage and inflammation in alcohol, the TGF-β/SMAD signaling pathway and α-SMA inhibitory action alleviates liver damage.

도 8 에서 보이는 바와 같이, Alcohol 그룹에서는 TGF-β, SMAD-4, α-SMA 유전자의 발현량이 현저히 증가하였으며, GSH-YE 그룹 및 HEM 그룹은 TGF-β, SMAD-4, α-SMA 유전자 발현량이 Alcohol 그룹 대비 현저히 감소하는 것을 확인할 수 있었다. 또한, HEM 그룹의 경우, 무처리 그룹인 N.A 그룹보다도 TGF-β, SMAD-4, α-SMA 유전자 발현량이 낮은 것을 확인하였다. As shown in Figure 8, the expression levels of TGF-β, SMAD-4, and α-SMA genes were significantly increased in the Alcohol group, and the expression of TGF-β, SMAD-4, and α-SMA genes in the GSH-YE and HEM groups It was confirmed that the amount was significantly decreased compared to the Alcohol group. In addition, in the case of the HEM group, it was confirmed that the TGF-β, SMAD-4, and α-SMA gene expression levels were lower than that of the non-treated N.A group.

이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특허청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.So far, the present invention has been looked at with respect to its preferred embodiments. Those skilled in the art to which the present invention pertains will be able to understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an illustrative rather than a limiting point of view. The scope of the present invention is shown in the claims rather than the foregoing description, and all differences within the equivalent scope will be construed as being included in the present invention.

Claims (4)

아이스플랜트 (Mesembryanthemum crystalinum) 추출물, 갈화 (Pueraria lobata flower) 추출물, 및 학명이 Artemisia indica인 쑥 추출물을 포함하는 숙취해소 또는 간 기능 개선용 식품조성물로,
상기 아이스플랜트 추출물, 갈화 추출물, 및 학명이 Artemisia indica인 쑥 추출물의 중량비는 1:2:2 내지 1:4:4 인 것인,
숙취해소 또는 간 기능 개선용 식품조성물.
A food composition for relieving hangover or improving liver function,
The weight ratio of the ice plant extract, the gall flower extract, and the mugwort extract having the scientific name Artemisia indica is 1: 2: 2 to 1: 4: 4,
A food composition for relieving hangover or improving liver function.
삭제delete 제 1항에 있어서,
상기 추출물은 각각 독립적으로 물, 탄소수 1 내지 4의 저급 알코올 또는 이들의 혼합 용매로 추출한 것인,
숙취해소 또는 간 기능 개선용 식품조성물.
According to claim 1,
The extracts are each independently extracted with water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof,
A food composition for relieving hangover or improving liver function.
제 1항에 있어서,
상기 식품은 음료, 환, 정제, 캡슐, 젤리, 발효유, 캔디, 아이스크림 형태인,
숙취해소 또는 간 기능 개선용 식품조성물.

According to claim 1,
The food is in the form of a beverage, pill, tablet, capsule, jelly, fermented milk, candy, ice cream,
A food composition for relieving hangover or improving liver function.

KR1020220118110A 2022-09-19 2022-09-19 Composition Comprising Mesembryanthemum crystalinum Extracts, Pueraria lobata flower Extracts, and Artemisia indica Extracts for Preventing of Alleviating Hangover and Improving Hepatic Function KR102506958B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020220118110A KR102506958B1 (en) 2022-09-19 2022-09-19 Composition Comprising Mesembryanthemum crystalinum Extracts, Pueraria lobata flower Extracts, and Artemisia indica Extracts for Preventing of Alleviating Hangover and Improving Hepatic Function

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020220118110A KR102506958B1 (en) 2022-09-19 2022-09-19 Composition Comprising Mesembryanthemum crystalinum Extracts, Pueraria lobata flower Extracts, and Artemisia indica Extracts for Preventing of Alleviating Hangover and Improving Hepatic Function

Publications (1)

Publication Number Publication Date
KR102506958B1 true KR102506958B1 (en) 2023-03-07

Family

ID=85513672

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020220118110A KR102506958B1 (en) 2022-09-19 2022-09-19 Composition Comprising Mesembryanthemum crystalinum Extracts, Pueraria lobata flower Extracts, and Artemisia indica Extracts for Preventing of Alleviating Hangover and Improving Hepatic Function

Country Status (1)

Country Link
KR (1) KR102506958B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960000088A (en) * 1994-06-14 1996-01-25 서중일 Drink for removing hangover using browning
KR100574097B1 (en) 2004-09-01 2006-04-27 이행우 Functional food compositions having the effect on eliminating an alcoholic hangover and improvement of liver function
JP2010275288A (en) * 2009-05-29 2010-12-09 Ben's Lab Co Ltd Functional composition for preventing and improving hangover, food and food additive containing the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960000088A (en) * 1994-06-14 1996-01-25 서중일 Drink for removing hangover using browning
KR100574097B1 (en) 2004-09-01 2006-04-27 이행우 Functional food compositions having the effect on eliminating an alcoholic hangover and improvement of liver function
JP2010275288A (en) * 2009-05-29 2010-12-09 Ben's Lab Co Ltd Functional composition for preventing and improving hangover, food and food additive containing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"국내대표 열대작물 브랜드 만들 것" 경남일보. [online], 2018.12.03., [2022.11.21. 검색], 인터넷: <URL: http://www.gnnews.co.kr/news/articleView.html?idxno=344741> 1부.* *
숙취엔 땀 흘리고 화장실 자주 가라. 뉴시스. [online], 2008.08.19., [2022.11.21. 검색], 인터넷: <URL: https://n.news.naver.com/mnews/article/print/003/0002242534> 1부.* *

Similar Documents

Publication Publication Date Title
CA2732306C (en) Muscadine compositions with improved anti-oxidant activity
JP4589212B2 (en) Proanthocyanidin-containing food and process for producing the same
KR20140090453A (en) Composition comprising aronia extract for preventing and relieving hangover, and for protecting the alcohol-damaged hepatocyte
JP4751204B2 (en) Method for producing purified green tea extract
KR101281988B1 (en) Composition having eleutherococcus senticosus for treating hangover and improving liver function, and the preparation method thereof
US7846484B2 (en) Composition comprising Hovenia dulcis thunb. extract, Lindera obtusiloba blume extract, or herbal mixture extract thereof
KR101717698B1 (en) Composition comprising extract of Quercus acuta for prevention and treatment of hyperuricemia and metabolic disorders associated with hyperuricemia
US20190076496A1 (en) Polysaccharide digestion inhibitor
KR20160052855A (en) Pharmaceutical composition comprising fermented Aralia cordata Thunb for preventing or treating arthritis
KR101819026B1 (en) Composition for use of inhibition of stomach damage to alcohol or inhibition of alcohol uptake or relief of hangover comprising fermented extract of native plants from Jeju island
KR102506958B1 (en) Composition Comprising Mesembryanthemum crystalinum Extracts, Pueraria lobata flower Extracts, and Artemisia indica Extracts for Preventing of Alleviating Hangover and Improving Hepatic Function
US9173916B2 (en) Method of preparing a muscadine pomace extract
JP2012070726A (en) Composition for beauty food having improved bioavailability
JP2007131599A (en) Plant extract containing glycation-inhibiting ability and method for producing the same
KR101426921B1 (en) Composition comprising the porphyrinic compounds such as pheophorbide of Capsosiphon fulvescens for preventing or treating diabetes and diabetes complication, and antioxidant
JP2009274961A (en) Absorption promoter
KR101157096B1 (en) Composition for relieving hangover containing Bulnesia sarmienti extracts
KR101082598B1 (en) Hangover recovery drink comprising extracts of Hericium Erinaceum
KR101798205B1 (en) Food composition increased gamma-aminobutyric acid comprising fermentated barley leaf and corn silk as active ingredient
JP2006151838A (en) Carbohydrate digesting enzyme inhibitor
KR20200032460A (en) Composition containing h2-occluded calcium and having alcoholysis and acetaldehydelysis for hangover-relieving
KR101370679B1 (en) Method for manufacturing solid-state fermented Allium victorialis and Composition for preventing or treating anti-diabetes or anti-diabetic complication containing fermented Allium victorialis
JP2002104981A (en) Method for producing guarana extract, remedy and prophylactic for liver function failure and tumor immunopotentiator containing the guarana extract as active ingredient, and functional food containing the guarana extract
KR102216618B1 (en) Fermentation method of lactic acid bacteria using artichoke and its use
KR102283749B1 (en) Analysis method of standard quality comprising extracts of fat-removed and fermented tenebrio molitor

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant